Immunotherapy with checkpoint inhibitors is currently considered a cornerstone of metastatic renal clear cell cancer (mRCC) therapy. Despite the general improvement in the survival of patients with mRCC, there are some clinical situations that have not been specifically evaluated in clinical trials, such as the use of everolimus before nivolumab.
We performed a retrospective analysis evaluating the efficacy of nivolumab in the real-world setting, including a subset of patients with previous mTOR inhibitor therapy.
From a total of 56 patients, 25 were pre-treated with everolimus before receiving nivolumab. The overall progression-free survival (PFS), overall survival (OS), and objective response rate were 10.3, 21.3 months, and 34%, respectively. There were no statistically significant differences in patients who were or were not pre-treated with everolimus.
mRCC patients should be treated with checkpoint inhibitors and prior use of mTOR inhibitors should not be a definitive exclusion criterium.
In vivo (Athens, Greece). 0000 Jan [Epub]
Jindrich Kopecky, Ondrej Kubecek, Tomas Buchler, Bohuslav Melichar, Alexandr Poprach, Milada Zemanova, Jana Katolicka, Igor Kiss, Jaroslav Hajek, Hana Studentova, Martina Spisarova
Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; ., Department of Oncology and Radiotherapy Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic., Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic., Department of Oncology, First Faculty of Medicine Charles University and General University Hospital, Prague, Czech Republic., Department of Oncology, St. Anne's University Hospital Brno, Brno, Czech Republic., Department of Oncology, University Hospital Ostrava, Ostrava, Czech Republic., Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic.